Individualizing Treatment in T2D Management:
Novel Therapies for Improved Patient Outcomes

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from an audioconference held August, 31, 2017

This activity is valid from September 1, 2017 to August 31, 2018

Instructions for CME/CNE: Complete the pre test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Boehringer Ingelheim Pharmaceuticals and Lilly USA LLC Alliance,
Lilly USA LLC, and Sanofi

While the prevalence of diabetes continues to rise, a new generation of treatments has become available in the past few years. Despite new regimens, barriers to care, such as patient adherence and economic burden, still exist. It has been estimated that people diagnosed with diabetes, on average, have medical expenditures that are approximately 2.3 times higher than what expenditures would be in the absence of diabetes. The price tag associated with treatment of type 2 DM increases with disease severity, as more and more dollars are spent managing the significant comorbidities associated with advanced type 2 DM. The management of type 2 DM remains a major challenge as many patients continue to struggle with achieving therapeutic goals, including control of A1C level, blood pressure, cholesterol, and weight. Fortunately, recent advances in treatments for Type 2 Diabetes have given healthcare professionals the ability to individualize care. New data and guideline updates offer best practices in regard to the role of mono and combination therapies. Treatments have become available that allow the individualization of T2DM management. There have been many questions in member surveys and past program evaluations about the best practices in regard to the role of combination therapies comprised of SGLT-2 inhibitors in the management of type 2 diabetes, and new data and guidelines updates showing the benefits and risks of these new therapies.

Upon Completion of this activity, participants will be able to:

  • Compare and contrast safety, efficacy, mechanisms of action of current and emerging therapies for individualized target goals in T2D

  • Apply new clinical data and guidelines on combination therapies for glycemic management of T2D patients

  • Assess importance of customizing A1c goals based on individual patient characteristics

  • Recognize optimal use of SGLT2i, GLP-1 RA, newer insulins

  • Analyze barriers to effective, timely combination therapy initiation and implementation in T2D management

  • Examine recent clinical data on combination therapy for glycemic control and CV risk in T2D

Faculty: Zachary Bloomgarden, MD, MACE
Clinical Professor, Icahn School of Medicine at Mount Sinai
Editor, Journal of Diabetes


Dr. Bloomgarden serves as on the speaker’s bureau to Genentech/Roche; serves as a consultant for Astra Zeneca, Johnson & Johnson, Merck, Intarcia, Novartis and has received income in any amount from Merck, Astra Zeneca, Johnson & Johnson and is a stockholder of Allergan, Pfizer, Zimmer Biomet, Novartis. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Will Williams has no real or perceived financial relationships to disclose.
Jacquelyn Smith has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This presentation is supported by educational grants from
Boehringer Ingelheim Pharmaceuticals and Lilly USA LLC Alliance,
Lilly USA LLC, and Sanofi

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue